Boehringer Ingelheim acquires ViraTherapeutics for €210m in strategic cancer immunotherapy expansion
German pharmaceutical powerhouse Boehringer Ingelheim has acquired Austria-based oncolytic virus developer ViraTherapeutics for €210 million, cementing its strategic pursuit of innovative, viral-based cancer immunotherapy solutions. This acquisition, rooted in a long-standing partnership established in 2016, aims to propel the development of cutting-edge oncolytic virus therapies, particularly targeting “cold” tumors that have shown resistance to traditional […]